Wegovy gets even cheaper in South Africa as Novo Nordisk battles Eli Lilly
Novo Nordisk has announced its second price reduction for its weight-loss medication, Wegovy, in South Africa, following its market debut in August. This decis…
Novo Nordisk has announced its second price reduction for its weight-loss medication, Wegovy, in South Africa, following its market debut in August. This decision, conveyed by local executives on Wednesday, is a direct response to the intense competitive landscape, where rival Eli Lilly currently holds a leading position.
Novo Nordisk (NVO) currently holds an RS Score of 65.70, ranking it in the 36.64th percentile both within its country and sector. The company demonstrates strong fundamentals in several areas, with its Valuation (96.40), Growth (95.54), and Profitability (96.05) sections all scoring above 80. However, its Momentum (11.59) and EPS Revisions (64.00) scores are comparatively weaker. Want to discover which stocks rank the highest? Start your free 7-day trial at rankedstocks.com.